Guardant Health (FRA:5GH) Beta: 1.9079 (As of Jun. 26, 2026)


FRA:5GH Guardant Health Inc FRA:5GH
67 GF Score
Price €122.16
GF Value €51.63
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Guardant Health Beta?

Guardant Health FRA:5GH +1.63% 67 Beta is 1.9079 as of Jun. 26, 2026. GuruFocus rates FRA:5GH with a GF Score™ of 67/100 and a GF Value™ of €51.63 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Guardant Health's Beta is 1.9079.


Guardant Health  (FRA:5GH) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Guardant Health Beta Related Terms


Guardant Health Beta Historical Data

* Premium members only.

The historical data trend for Guardant Health's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guardant Health Beta Chart

Guardant Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.76 0.07 0.28

Guardant Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.04 0.58 0.80 0.28 0.96

FRA:5GH vs LH, DGX, MEDP: Beta Comparison

For the Diagnostics & Research subindustry, Guardant Health's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guardant Health Beta vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Beta distribution charts can be found below:

* The bar in red indicates where Guardant Health's Beta falls into.


FRA:5GH
67GF Score
Guardant Health Inc FRA:5GH
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guardant Health Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.9079 mean?
Guardant Health (FRA:5GH) has a Beta of 1.9079 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Guardant Health and its competitors.
Is Guardant Health's Beta too high?
Guardant Health's current Beta is 1.9079. Overall, Guardant Health has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guardant Health's Beta compare to LH and DGX?
Guardant Health's Beta of 1.9079 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Diagnostics & Research company?
A good Beta depends on the Medical Diagnostics & Research industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Guardant Health and its competitors. Guardant Health's current Beta is 1.9079. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardant Health stock overvalued right now?
Based on GuruFocus' analysis, Guardant Health (FRA:5GH) is currently considered Significantly Overvalued. The stock's GF Value™ is €51.63, compared to a current price of €122.16 — trading 136.6% above its estimated fair value. The current Beta is 1.9079. Guardant Health's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Guardant Health (FRA:5GH), the current Beta is 1.9079 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guardant Health (FRA:5GH) Overvalued in 2026?

Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued. The current stock price of €122.16 is trading 136.6% above its estimated GF Value™ of €51.63. GuruFocus considers Guardant Health to be Significantly Overvalued.

Key valuation signals for FRA:5GH:

  • Beta: 1.9079
  • GF Value™: €51.63 vs. price of €122.16 (136.6% above fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the FRA:5GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Guardant Health Business Description

Other Exchanges GH:USA1GH:Italy5GH:Germany
Address 3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
67GF Score

Get the complete analysis for FRA:5GH

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€122.16
Price
€51.63
GF Value